Medical Historical Cash Flow

MVP Stock

0.43 0.01 2.38%

Analysis of Medical Developments cash flow over time is an excellent tool to project Medical Developments future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 2.5 M or End Period Cash Flow of 8.2 M as it is a great indicator of Medical Developments ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Medical Developments latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medical Developments is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medical Developments International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Medical Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Medical balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Medical's non-liquid assets can be easily converted into cash.

Medical Developments Cash Flow Chart

At this time, Medical Developments' Begin Period Cash Flow is comparatively stable compared to the past year. Depreciation is likely to gain to about 4.1 M in 2025, despite the fact that Free Cash Flow is likely to grow to (11.9 M).

Begin Period Cash Flow Capital Expenditures End Period Cash Flow Dividends Paid

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Medical Developments to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Medical Developments operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Most accounts from Medical Developments' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Medical Developments current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medical Developments International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Medical Developments cash flow statement Correlations

	Sale Purchase Of Stock	Change In Cash	Free Cash Flow	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	End Period Cash Flow	Dividends Paid	Change To Inventory	Change To Account Receivables	Stock Based Compensation	Change In Working Capital	Net Borrowings	Change To Operating Activities	Change To Netincome	Change To Liabilities	Investments	Issuance Of Capital Stock
Sale Purchase Of Stock		-0.13	0.39	-0.44	-0.63	-0.33	-0.51	0.4	-0.62	-0.53	0.14	-0.01	-0.54	0.05	0.24	-0.05	0.39	-0.59	0.07	-0.1
Change In Cash	-0.13		0.47	-0.59	-0.25	-0.11	-0.11	0.5	0.43	-0.06	0.36	-0.33	-0.24	-0.65	-0.36	0.32	0.56	-0.39	-0.52	0.43
Free Cash Flow	0.39	0.47		-0.79	-0.76	0.03	-0.67	0.57	-0.38	-0.68	0.41	-0.29	-0.7	-0.06	-0.25	0.73	0.48	-0.62	-0.45	0.04
Begin Period Cash Flow	-0.44	-0.59	-0.79		0.86	0.4	0.65	-0.73	0.45	0.59	-0.48	0.21	0.76	0.18	-0.1	-0.36	-0.52	0.79	0.51	-0.36
Depreciation	-0.63	-0.25	-0.76	0.86		0.57	0.55	-0.85	0.63	0.89	-0.16	0.21	0.95	0.06	-0.17	-0.34	-0.51	0.83	0.51	0.11
Other Non Cash Items	-0.33	-0.11	0.03	0.4	0.57		-0.12	-0.74	0.23	0.49	0.24	-0.05	0.62	0.18	-0.43	0.36	-0.33	0.58	0.5	0.17
Capital Expenditures	-0.51	-0.11	-0.67	0.65	0.55	-0.12		-0.17	0.66	0.4	-0.66	0.15	0.37	-0.23	-0.08	-0.38	-0.22	0.57	-0.11	-0.29
Net Income	0.4	0.5	0.57	-0.73	-0.85	-0.74	-0.17		-0.2	-0.79	-0.07	-0.35	-0.85	-0.44	0.08	0.24	0.66	-0.76	-0.73	-0.2
End Period Cash Flow	-0.62	0.43	-0.38	0.45	0.63	0.23	0.66	-0.2		0.51	-0.2	-0.15	0.52	-0.56	-0.49	-0.07	0.08	0.39	-0.04	0.02
Dividends Paid	-0.53	-0.06	-0.68	0.59	0.89	0.49	0.4	-0.79	0.51		0.06	0.3	0.87	0.06	-0.1	-0.41	-0.53	0.74	0.52	0.49
Change To Inventory	0.14	0.36	0.41	-0.48	-0.16	0.24	-0.66	-0.07	-0.2	0.06		0.15	-0.07	0.08	-0.09	0.11	0.23	-0.44	0.13	0.65
Change To Account Receivables	-0.01	-0.33	-0.29	0.21	0.21	-0.05	0.15	-0.35	-0.15	0.3	0.15		0.08	0.55	0.26	-0.61	-0.21	0.11	0.07	0.07
Stock Based Compensation	-0.54	-0.24	-0.7	0.76	0.95	0.62	0.37	-0.85	0.52	0.87	-0.07	0.08		0.09	-0.14	-0.26	-0.55	0.8	0.57	0.23
Change In Working Capital	0.05	-0.65	-0.06	0.18	0.06	0.18	-0.23	-0.44	-0.56	0.06	0.08	0.55	0.09		0.13	-0.01	-0.7	0.21	0.26	-0.02
Net Borrowings	0.24	-0.36	-0.25	-0.1	-0.17	-0.43	-0.08	0.08	-0.49	-0.1	-0.09	0.26	-0.14	0.13		-0.56	0.03	-0.16	-0.08	0.02
Change To Operating Activities	-0.05	0.32	0.73	-0.36	-0.34	0.36	-0.38	0.24	-0.07	-0.41	0.11	-0.61	-0.26	-0.01	-0.56		0.02	-0.11	-0.25	-0.06
Change To Netincome	0.39	0.56	0.48	-0.52	-0.51	-0.33	-0.22	0.66	0.08	-0.53	0.23	-0.21	-0.55	-0.7	0.03	0.02		-0.72	-0.43	-0.14
Change To Liabilities	-0.59	-0.39	-0.62	0.79	0.83	0.58	0.57	-0.76	0.39	0.74	-0.44	0.11	0.8	0.21	-0.16	-0.11	-0.72		0.4	-0.01
Investments	0.07	-0.52	-0.45	0.51	0.51	0.5	-0.11	-0.73	-0.04	0.52	0.13	0.07	0.57	0.26	-0.08	-0.25	-0.43	0.4		0.15
Issuance Of Capital Stock	-0.1	0.43	0.04	-0.36	0.11	0.17	-0.29	-0.2	0.02	0.49	0.65	0.07	0.23	-0.02	0.02	-0.06	-0.14	-0.01	0.15

Click cells to compare fundamentals

Medical Developments Account Relationship Matchups

Medical Developments cash flow statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Sale Purchase Of Stock	(727K)	(3K)	(1.7M)	(533K)	(479.7K)	(455.7K)
Change In Cash	20.7M	(15.9M)	4.3M	(14.9M)	(13.4M)	(12.8M)
Free Cash Flow	(15.4M)	(15.9M)	(24.2M)	(13.9M)	(12.6M)	(11.9M)
Begin Period Cash Flow	15.5M	36.3M	20.4M	24.7M	28.4M	29.8M
Other Cashflows From Financing Activities	(141K)	(215K)	(253K)	(274K)	(315.1K)	(330.9K)
Depreciation	3.7M	2.9M	3.1M	3.4M	3.9M	4.1M
Other Non Cash Items	8.9M	9.8M	(5.4M)	22.6M	26.0M	27.3M
Capital Expenditures	6.6M	5.2M	7.7M	3.2M	3.6M	2.5M
Total Cash From Operating Activities	(8.8M)	(10.7M)	(16.5M)	(10.8M)	(9.7M)	(9.2M)
Net Income	(12.6M)	(12.4M)	(5.6M)	(41.0M)	(36.9M)	(35.0M)
Total Cash From Financing Activities	36.1M	142K	28.1M	(807K)	(928.1K)	(881.6K)
End Period Cash Flow	36.3M	20.4M	24.7M	9.7M	11.2M	8.2M
Dividends Paid	2.1M	35.5M	139K	26.4M	30.3M	31.9M
Change To Inventory	154K	(1.4M)	(1.8M)	(393K)	(353.7K)	(371.4K)
Other Cashflows From Investing Activities	(5.2M)	(4.0M)	(5.3M)	(2.4M)	(2.1M)	(2.2M)
Change To Account Receivables	1.4M	(2.5M)	(2.9M)	1.9M	1.7M	1.8M
Stock Based Compensation	91K	1.2M	1.0M	1.3M	1.4M	1.5M
Change In Working Capital	(9.9M)	(3.6M)	(2.5M)	4.2M	3.8M	4.0M
Net Borrowings	(288K)	(232K)	(215K)	(253K)	(227.7K)	(239.1K)
Total Cashflows From Investing Activities	(8.5M)	(6.5M)	(5.2M)	(7.1M)	(6.4M)	(6.7M)
Change To Operating Activities	(1.7M)	(10.2M)	(19K)	(154K)	(138.6K)	(131.7K)
Change To Netincome	(2.6M)	7.5M	1.7M	(12.1M)	(10.9M)	(10.3M)
Change To Liabilities	2.0M	1.0M	903K	2.4M	2.7M	2.9M
Investments	(6.5M)	(5.2M)	(7.1M)	(3.2M)	(3.6M)	(3.8M)
Issuance Of Capital Stock	400K	37.1M	360K	30M	34.5M	20.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Medical Stock Analysis

When running Medical Developments' price analysis, check to measure Medical Developments' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medical Developments is operating at the current time. Most of Medical Developments' value examination focuses on studying past and present price action to predict the probability of Medical Developments' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medical Developments' price. Additionally, you may evaluate how the addition of Medical Developments to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC